Ascendis Pharma announces U.S. FDA approval of Skytrofa (lonapegsomatropin-tcgd), the first once weekly treatment for paediatric growth hormone deficiency

Ascendis Pharma

25 August 2021 - Availability in the U.S. expected shortly supported by a full suite of patient support programs.

Ascendis Pharma today announced that the U.S. FDA has approved Skytrofa (lonapegsomatropin-tcgd) for the treatment of paediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone.

Read Ascendis Pharma press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , Paediatrics